NCT04152200 - A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 21, 2020

Primary Completion Date

May 18, 2021

Study Completion Date

June 23, 2025

Conditions

Primary Hyperoxaluria Type 1Primary Hyperoxaluria

Interventions

DRUG

Lumasiran

Lumasiran will be administered by subcutaneous (SC) injection.

Trial Locations (14)

Clinical Trial Site, Rochester

Clinical Trial Site, Houston

Clinical Trial Site, Garran

Clinical Trial Site, Brussels

Clinical Trial Site, Bron

Clinical Trial Site, Lyon

Clinical Trial Site, Haifa

Clinical Trial Site, Nahariya

Clinical Trial Site, Rome

Clinical Trial Site, Irbid

Clinical Trial Site, Beirut

Clinical Trial Site, Amsterdam

Clinical Trial Site, Yenimahalle

Clinical Trial Site, Dubai